Liu Lunfei, Liu Wenting, Zheng Yuxin, Chen Jisu, Zhou Jiong, Dai Huatuo, Cai Suiqing, Liu Jianjun, Zheng Min, Ren Yunqing
Department of Dermatology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
School of Public Health and Management, Hubei University of Medicine, Shiyan, Hubei, China.
BMC Syst Biol. 2019 Apr 5;13(Suppl 2):29. doi: 10.1186/s12918-019-0698-7.
Anti-tumor necrosis factor alpha (TNF- α) therapy has made a significant impact on treating psoriasis. Despite these agents being designed to block TNF- α activity, their mechanism of action in the remission of psoriasis is still not fully understood at the molecular level.
To better understand the molecular mechanisms of Anti-TNF- α therapy, we analysed the global gene expression profile (using mRNA microarray) in peripheral blood mononuclear cells (PBMCs) that were collected from 6 psoriasis patients before and 12 weeks after the treatment of etanercept. First, we identified 176 differentially expressed genes (DEGs) before and after treatment by using paired t-test. Then, we constructed the gene co-expression modules by weighted correlation network analysis (WGCNA), and 22 co-expression modules were found to be significantly correlated with treatment response. Of these 176 DEGs, 79 DEGs (M_DEGs) were the members of these 22 co-expression modules. Of the 287 GO functional processes and pathways that were enriched for these 79 M_DEGs, we identified 30 pathways whose overall gene expression activities were significantly correlated with treatment response. Of the original 176 DEGs, 19 (GO_DEGs) were found to be the members of these 30 pathways, whose expression profiles showed clear discrimination before and after treatment. As expected, of the biological processes and functionalities implicated by these 30 treatment response-related pathways, the inflammation and immune response was the top pathway in response to etanercept treatment, and some known TNF- α related pathways, such as molting cycle process, hair cycle process, skin epidermis development, regulation of hair follicle development, were implicated. Furthermore, additional novel pathways were also suggested, such as heparan sulfate proteoglycan metabolic process, vascular endothelial growth factor production, whose transcriptional regulation may mediate the response to etanercept treatment.
Through global gene expression analysis in PBMC of psoriasis patient and subsequent co-expression module based pathway analyses, we have identified a group of functionally coherent and differentially expressed genes (DEGs) and related pathways, which has not only provided new biological insight about the molecular mechanism of anti-TNF- α treatment, but also identified several genes whose expression profiles can be used as potential biomarkers for anti-TNF- α treatment response in psoriasis.
抗肿瘤坏死因子α(TNF-α)疗法对银屑病的治疗产生了重大影响。尽管这些药物旨在阻断TNF-α的活性,但其在银屑病缓解中的作用机制在分子水平上仍未完全了解。
为了更好地理解抗TNF-α疗法的分子机制,我们分析了从6名银屑病患者治疗前和接受依那西普治疗12周后收集的外周血单核细胞(PBMC)中的全局基因表达谱(使用mRNA微阵列)。首先,我们通过配对t检验确定了治疗前后176个差异表达基因(DEG)。然后,我们通过加权相关网络分析(WGCNA)构建了基因共表达模块,发现22个共表达模块与治疗反应显著相关。在这176个DEG中,79个DEG(M_DEG)是这22个共表达模块的成员。在为这79个M_DEG富集的287个GO功能过程和通路中,我们确定了30个通路,其整体基因表达活性与治疗反应显著相关。在最初的176个DEG中,发现19个(GO_DEG)是这30个通路的成员,其表达谱在治疗前后表现出明显的差异。正如预期的那样,在这30个与治疗反应相关的通路所涉及的生物学过程和功能中,炎症和免疫反应是对依那西普治疗反应的首要通路,并且涉及一些已知的与TNF-α相关的通路,如蜕皮周期过程、毛发周期过程、皮肤表皮发育、毛囊发育调节。此外,还提出了其他新的通路,如硫酸乙酰肝素蛋白聚糖代谢过程、血管内皮生长因子产生,其转录调控可能介导对依那西普治疗的反应。
通过对银屑病患者PBMC中的全局基因表达分析以及随后基于共表达模块的通路分析,我们确定了一组功能相关且差异表达的基因(DEG)和相关通路,这不仅为抗TNF-α治疗的分子机制提供了新的生物学见解,还确定了几个基因,其表达谱可作为银屑病中抗TNF-α治疗反应的潜在生物标志物。